News

Programme Preview

posted on

The IAS Conference on HIV Science is the largest open scientific conference on HIV and AIDS related issues, boasting a best-in-class scientific programme.

In addition to a strong abstract-driven programme, IAS 2017 will offer symposia, workshops and interactive sessions developed by an international committee of HIV scientists and professionals.

Here is a first glimpse of what you can expect in Paris, which you can browse in our preview of the conference programme:

Understanding HIV pathogenesis

  • State-of-the-art technological advances to help us better understand HIV and the immune response
  • The factors that influence HIV acquisition and replication, and how this knowledge can help us prevent transmissions
  • How early treatment may promote control of HIV and prevent the establishment of chronic infection

New prevention technologies

  • The challenges of designing studies to assess the efficacy of PrEP, vaccines and antibodies for HIV prevention
  • What we know about adaptive and innate immunity to HIV, and how this can drive the development of successful HIV vaccines
  • The current evidence on the effectiveness of intermittent PrEP “on demand”, and remaining questions to be answered

Clinical management of HIV

  • The role of persistent immune activation and inflammation in the long-term health of people living with HIV who are on treatment
  • How early treatment may allow for alternatives to lifelong triple therapy: recent results and their health and cost implications
  • Using mobile health (mHealth) technologies and social media platforms for clinicians, researchers and patients at all stages of the treatment cascade

Co-infections and co-morbidities

  • Tuberculosis in Europe and the role of migration: epidemiology, clinical realities, and new diagnostic tools and treatment options
  • The clinical and economic benefits and tradeoffs of integrating HIV care with services for related infections and morbidities
  • Overcoming barriers to delivering the cure for hepatitis C: treatment costs, service delivery, screening, and prevalence data

Access and equity

  • Connecting the dots between transgender clinical care services and HIV prevention and care services
  • How new approaches to drug pricing could expand access to treatment for HIV, tuberculosis, and hepatitis C
  • Why HIV is more prevalent in migrant communities, and how public health policies can increase access to prevention and care

REGISTER NOW

| Return